Ion Exchange India Q1 FY27 Results: Revenue Growth Amidst Profitability Pressure

Revenue from operations increased by 20% to Rs 701 crore in Q1 FY27.
Consolidated EBITDA saw a significant decline of 49% to Rs 32 crore.

Reader Takeaway: Strong revenue growth is positive, but legacy project issues continue to pressure margins and profitability.

What just happened

Ion Exchange (India) Limited announced its consolidated financial results for the first quarter of fiscal year 2027. The company reported a healthy 20% year-on-year increase in operating income, reaching Rs 701 crore. However, consolidated Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) experienced a significant drop of 49%, falling to Rs 32 crore, with the EBITDA margin contracting to 4.54%. Net Profit After Tax (PAT) was Rs 3 crore.

Why this matters

The sharp decline in profitability, despite revenue growth, signals ongoing operational challenges. Shareholders will be concerned about the factors impacting EBITDA, particularly the costs associated with project execution and the continued drag from legacy projects in the Treatment Solutions segment. The company's ability to resolve these issues and improve margins will be crucial for future performance.

The backstory

Ion Exchange has restructured its reporting, dividing the former engineering division into Treatment Solutions, Industrial Products, and Lifecycle Services to provide better business transparency. Approximately 60% of its business now consists of products, chemicals, and services, with 40% in treatment solutions. The Roha resin manufacturing facility has been commissioned, offering a five-fold capacity expansion for its ion exchange resins business, aiming to boost global market share.

What changes now

The new segmental reporting provides a clearer view of individual business unit performance. The company aims to leverage the expanded capacity at the Roha facility. However, profitability, especially in the Treatment Solutions segment, remains impacted by legacy government-funded projects, like the U.P. project, which are dependent on fund flows for final closure. The unexecuted portion of this project is about 11% of the total order backlog.

Risks to watch

The primary risk remains the continued impact of legacy projects on profitability, particularly in the Treatment Solutions segment. Ramping up utilization at the new Roha facility and managing its costs effectively will be critical. Achieving double-digit profitability will depend on margin improvement in key segments like Treatment Solutions and Specialty Chemicals.

Peer comparison

While a direct, up-to-the-minute peer comparison on Q1 FY27 financials is not readily available, the water and wastewater treatment sector, along with specialty chemicals, typically sees varied profitability. Companies with significant project-based revenue often face margin volatility due to execution complexities and payment cycles. Ion Exchange's reported margins, especially the consolidated EBITDA margin of 4.54%, are on the lower side compared to some specialty chemical players, but may be more in line with large-scale project-heavy engineering firms.

Context metrics (time-bound)

• Order Book as of June 2026: Rs 2,473 crore.
• Bid Pipeline: Rs 9,777 crore.
• Post-quarter win: Contract with Hyundai worth approximately USD 52 million.

What to track next

Investors should closely monitor the progress in normalizing operations at the Roha facility and the successful resolution of outstanding payments and project closures for the legacy contracts. The company's ability to improve EBIT margins across segments, particularly in Treatment Solutions and Specialty Chemicals, will be key indicators for future performance. The impact of the large international contract with Hyundai will also be important to track in subsequent quarters.